Novo Nordisk CEO signals new appetite for risk in obesity deals

Core Viewpoint - Novo Nordisk's CEO Mike Doustdar is determined to pursue the company and its portfolio of experimental obesity drugs despite Pfizer's $7.3 billion rival bid for Metsera [1] Company Summary - Novo Nordisk is actively engaged in the competitive landscape of obesity drug development, indicating a strong commitment to its research and development efforts [1]